Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

被引:6
|
作者
Figueroa, R. [1 ]
Alfonso, A. [1 ]
Lopez-Picazo, J. [2 ]
Gil-Bazo, I. [2 ]
Garcia-Mouriz, A. [3 ]
Hermida, J. [4 ,5 ]
Paramo, J. A. [1 ,5 ]
Lecumberri, R. [1 ,5 ]
机构
[1] Univ Clin Navarra, Hematol Serv, Ave Pio XII 36, Pamplona 31008, Spain
[2] Univ Clin Navarra, Dept Oncol, Pamplona, Spain
[3] Univ Clin Navarra, Informat Serv, Pamplona, Spain
[4] Univ Navarra, Ctr Appl Med Res, Pamplona, Spain
[5] Inst Salud Carlos III, Ctr Invest Biomed Red CIBER CV, Madrid, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2019年 / 21卷 / 06期
关键词
Cancer; Electronic alerts; Low molecular weight heparin; Prophylaxis; Venous thromboembolism; PREVENT VENOUS THROMBOEMBOLISM; CLINICAL-PRACTICE; ELECTRONIC ALERTS; THROMBOPROPHYLAXIS; RISK;
D O I
10.1007/s12094-018-1986-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThromboprophylaxis use among medical inpatients, including cancer patients, is suboptimal. We aimed to evaluate the impact of a novel multiscreen version (v2.0) of an e-alert system for VTE prevention in hospitalised cancer medical patients compared to the original software.MethodsProspective study including 989 consecutive adult cancer patients with high-risk of VTE. Patients were followed-up 30days post-discharge. Two periods were defined, according to the operative software.ResultsE-alert v2.0 was associated with an increase in the use of LMWH prophylaxis (65.5% vs. 72.0%); risk difference (95% CI) 0.064 (0.0043-0.12). Only 16% of patients in whom LMWH prophylaxis was not prescribed lacked a contraindication. No significant differences in the rates of VTE (2.9% vs. 3.2%) and major bleeding (2.7% vs. 4.0%) were observed.ConclusionsE-alert v2.0 further increased the use of appropriate thromboprophylaxis in hospitalised cancer patients, although was not associated with a reduction in VTE incidence.
引用
收藏
页码:805 / 809
页数:5
相关论文
共 50 条
  • [41] Impact of the COVID-19 pandemic on diagnosing and treatment referrals of lung cancer patients: A single-centre experience
    Janzic, U.
    Mohorcic, K.
    Adamic, K.
    Malovrh, M. Marc
    ANNALS OF ONCOLOGY, 2021, 32 : S1151 - S1151
  • [42] BRCA mutation testing rates among breast cancer patients meeting testing criteria: A single-centre experience
    Boianu, M.
    Daaboul, N.
    Speranza, G.
    Prady, C.
    Soldera, S.
    Martel, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S32 - S32
  • [43] Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome
    Murthy, Vidhya
    Wilson, Jacqueline
    Suhr, Julie
    James, Lydia
    Tombs, Harley
    Shereef, Elmoamly
    Nikolousis, Emmanuel
    ESMO OPEN, 2019, 4 (02)
  • [44] Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience
    Tagliaferri, Annarita
    Matichecchia, Annalisa
    Rivolta, Gianna F.
    Riccardi, Federica
    Quintavalle, Gabriele
    Benegiamo, Anna
    Rossi, Rossana
    Coppola, Antonio
    BLOOD TRANSFUSION, 2020, 18 (05) : 374 - 385
  • [45] Effect of bladder cancer variant histology on survival outcome in patients treated with radical cystectomy: A single-centre experience
    Komina, Selim
    Petrusevska, Gordana
    Janevska, Vesna
    Jovanovic, Rubens
    Zdravkovski, Pance
    Saidi, Skender
    Zafirovska, Beti Ivanovska
    Topuzovska, Sonja
    UROLOGY ANNALS, 2021, 13 (03) : 288 - 295
  • [46] Single-centre experience with Renal PatientView, a web-based system that provides patients with access to their laboratory results
    Alexander Woywodt
    Kervina Vythelingum
    Scott Rayner
    John Anderton
    Aimun Ahmed
    Journal of Nephrology, 2014, 27 : 521 - 527
  • [47] Anidulafungin primary prophylaxis in 28 high-risk patients undergoing allogeneic haematopoietic stem cell transplantation: a single-centre experience
    Clerici, D.
    Corti, C.
    Matteazzi, F.
    Greco, R.
    Assanelli, A.
    Lunghi, F.
    Malato, S.
    Giglio, F.
    Vago, L.
    Gentner, B.
    Fumagalli, L.
    Marcatti, M.
    Bernardi, M.
    Ciceri, F.
    Peccatori, J.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S228 - S228
  • [48] Cytomegalovirus infection and disease in patients undergoing unrelated cord blood transplant receiving prophylaxis with valgancyclovir or gancyclovir. Single-centre experience
    Montesinos, P.
    Sanz, J.
    Weiss, S.
    Cantero, S.
    Sanz, G.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S270 - S270
  • [49] Impact of intermediate-dose prophylaxis on progression of haemarthropathy in patients with severe haemophilia A: A 10-year, single-centre experience in Korea
    Kim, Ju Y.
    Lee, Da J.
    Chun, Tong J.
    You, Chur W.
    HAEMOPHILIA, 2018, 24 (06) : E402 - E409
  • [50] Single-centre experience with Renal PatientView, a web-based system that provides patients with access to their laboratory results
    Woywodt, Alexander
    Vythelingum, Kervina
    Rayner, Scott
    Anderton, John
    Ahmed, Aimun
    JOURNAL OF NEPHROLOGY, 2014, 27 (05) : 521 - 527